In Reply to “Letter Regarding ‘Dose-Response of Tenapanor in Patients With Hyperphosphatemia Undergoing Hemodialysis in Japan—A Phase 2 Randomized Trial’”

Detalles Bibliográficos
Autores principales: Inaba, Masaaki, Une, Yotaro, Ikejiri, Kazuaki, Kanda, Hironori, Fukagawa, Masafumi, Akizawa, Tadao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9263242/
https://www.ncbi.nlm.nih.gov/pubmed/35812269
http://dx.doi.org/10.1016/j.ekir.2022.05.023

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9263242/
https://www.ncbi.nlm.nih.gov/pubmed/35812269
http://dx.doi.org/10.1016/j.ekir.2022.05.023

Ejemplares similares